Your session is about to expire
← Back to Search
Monoclonal Antibodies
CNTY-101 for Lupus (CALiPSO-1 Trial)
Phase 1
Recruiting
Research Sponsored by Century Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participants must have a diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus for at least 6 months.
Participants must have elevated anti- double stranded deoxyribonucleic acid (anti-dsDNA) and/or elevated anti-Smith antibody test at Screening (a single retest of previously positive participants who were negative at screening will be allowed).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called CNTY-101 in people with autoimmune diseases like lupus. The study will determine the safety and effectiveness of different doses of the drug in patients who have
Who is the study for?
This trial is for people with tough-to-treat B cell-mediated autoimmune diseases, like severe lupus. They should have a specific diagnosis of SLE for at least 6 months and active disease as shown by certain test scores. Those with stable diabetes or hypothyroidism can join if their condition has been under control for over a month.
What is being tested?
CALiPSO-1 is testing CNTY-101's safety and effectiveness in patients with refractory autoimmune conditions. It involves giving participants CNTY-101 along with IL-2 and lymphodepleting chemotherapy to see how well it works against severe symptoms of diseases like lupus.
What are the potential side effects?
Possible side effects may include reactions related to the immune system, such as inflammation in different body parts due to IL-2, complications from lowering the body's immune cells through chemotherapy, and any specific effects tied to CNTY-101.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with SLE for at least 6 months.
Select...
I have high levels of anti-dsDNA or anti-Smith antibodies.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Arm D: CNTY-101 in DcSSC ParticipantsExperimental Treatment3 Interventions
During Part 1 (Dose Confirmation Phase), participants with DcSSC will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2.
After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.
During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1.
Group II: Arm C: CNTY-101 in IIM ParticipantsExperimental Treatment3 Interventions
During Part 1 (Dose Confirmation Phase), participants with IIM will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2.
After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.
During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1.
Group III: Arm B: CNTY-101 in LN ParticipantsExperimental Treatment3 Interventions
During Part 1 (Dose Confirmation Phase), participants with LN will undergo LDC followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental IL-2.
After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.
During Part 2 (Dose Expansion Phase), participants will receive treatments using the RP2R confirmed during Part 1.
Group IV: Arm A: CNTY-101 in SLE ParticipantsExperimental Treatment3 Interventions
During Part 1 (Dose Confirmation Phase), participants with SLE will undergo lymphodepleting chemotherapy (LDC) followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental human recombinant interleukin 2 (IL-2).
After completion of Cycle 1, CNTY-101 (without preceding LDC), will be administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.
During Part 2 (Dose Expansion Phase), participants will receive treatments using the recommended phase 2 regimen (RP2R) confirmed during Part 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IL-2
2007
Completed Phase 4
~1100
Find a Location
Who is running the clinical trial?
Century Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
450 Total Patients Enrolled